Jeantet advises Intrasense in the context of its share capital increase with preferential subscription rights
Paris, June 29, 2021 – Jeantet advised Intrasense in the context of its share capital increase with preferential subscription rights of the shareholders on the Euronext Growth Paris market for a total amount of €4.9 million.
Intrasense is a specialist in medical imaging software solutions and Myrian® designer, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up.
The share capital increase for which the subscription period opened from May 28 to June 15, 2021 inclusive, has been very successful despite a difficult market environment.
This share capital increase is part of Intrasense’s ambition to raise the funds necessary for its new phase of growth and innovation with the aim of bolstering its position and becoming a global leader in imaging for the oncology segment.
60% of the funds raised will be allocated to R&D for the development of a new oncology product line as well as for the evolution of the current Myrian product line. Approximately 40% of the proceeds will be allocated to the marketing and commercial development of Intrasense in Europe and China.
Invest Corporate Finance acted as Global Coordinator and financial advisor of Intrasense. Invest Securities acted as Lead Manager and Bookrunner.